News / US / cnbc
Eli Lilly Expands Biotech Portfolio via Merida Biosciences Acquisition
Health Technology · Biotechnology · cnbc · 2026-08-31
.SPX, LLY, GEV, HWM, @CL26V, @LCO26X, XLE, PEP, XLV, MDT, XLK, XLU
Eli Lilly is deploying its obesity-driven cash reserves to acquire Merida Biosciences for $2.875 billion, while GE Vernova shares face pressure from SpaceX manufacturing rumors.
What Happened
Strategic Biotech Acquisition: Eli Lilly has agreed to acquire Merida Biosciences for as much as $2.875 billion in cash to bolster its pipeline of autoimmune and allergy therapeutics. The deal focuses on biologics that target pathogenic autoantibodies, representing a distinct approach from traditional immune-suppressing treatments currently on the market.
Obesity Market Strategy: CEO David Ricks emphasized that the company is aggressively reinvesting profits from its obesity drug franchise into long-term medical innovation. Ricks also defended the value of obesity coverage for employers, arguing that treating the condition is more cost-effective than managing the long-term health complications associated with it.
Market Impact on GE Vernova: Shares of GE Vernova declined by 2% following social media commentary from Elon Musk regarding SpaceX's potential entry into turbine blade manufacturing. While the market reacted negatively, analysts at Jefferies suggested that significant barriers to entry and long production timelines will likely protect GE Vernova's pricing power for several years.
Broader Market Context: The trading session was characterized by rising energy prices due to geopolitical tensions and a hawkish outlook from the Federal Reserve, which pushed the 10-year Treasury yield to 4.75%. Investors are now looking ahead to key economic indicators, including the JOLTS report and manufacturing PMI data, to gauge the health of the U.S. economy.